Sep 09, 2021 / 08:15PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Great. Good afternoon again, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Fulcrum with us for the next session.
Quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosure.
So pleased to have Bryan Stuart, the CFO; and Chris Morabito, the CMO with us. I'm going to go backwards, Bryan, and we're going to start with -- or maybe not exactly backwards, but I thought we'd start with losmapimod, which is probably not the thing you've been getting the most questions on recently, but I think probably important to touch on because hopefully, we're going to have some sort of update here about regulatory discussions, et cetera.
Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot